# Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

Source: https://onco.cc/trials/nct07423585/  
OnCo record `nct07423585` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of tarlatamab in lung cancer, run by Asrar Alahmadi, now recruiting.

## Summary

Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer is a phase 2, interventional study registered as NCT07423585 by Asrar Alahmadi, with a registry enrolment figure of 39 participants, started 2026-03-20 and due to reach its primary completion in 2027-12-31. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Computed Tomography; Echocardiography Test; Electronic Health Record Review; Magnetic Resonance Imaging; Multigated Acquisition Scan; Questionnaire Administration; Tarlatamab. Conditions listed: Extensive Stage Lung Small Cell Carcinoma. Primary outcome: 6-month progression-free survival (PFS); Rapid progressive disease (PD) on tarlatamab rate probability (Interim analysis for futility monitoring). Lung eligibility wording from the registry: ", metastatic and/or recurrent) SCLC". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07423585
- Phase: 2
- Setting: A Front-Line Window-of-Opportunity Phase 2 Study of Tarlatamab (Bispecific T Cell Engager: DLL3-CD3) in Patients With Extensive-Stage Small-Cell Lung Cancer
- Sponsor: Asrar Alahmadi
- Enrolled: 39

## Sources

- ClinicalTrials.gov NCT07423585: https://clinicaltrials.gov/study/NCT07423585

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- drugs: [Tarlatamab](https://onco.cc/drugs/tarlatamab/)
- companies: [Amgen](https://onco.cc/companies/amgen/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07423585.json